Insider Spends US$52k Buying More Shares In Immix Biopharma

Whilst it may not be a huge deal, we thought it was good to see that the Immix Biopharma, Inc. (NASDAQ:IMMX) Independent Director, Jason Hsu, recently bought US$52k worth of stock, for US$2.23 per share. However, it only increased their shares held by 2.6%, and it wasn't a huge purchase by absolute value, either.

Check out our latest analysis for Immix Biopharma

The Last 12 Months Of Insider Transactions At Immix Biopharma

Notably, that recent purchase by Independent Director Jason Hsu was not the only time they bought Immix Biopharma shares this year. Earlier in the year, they paid US$4.88 per share in a US$267k purchase. That means that even when the share price was higher than US$2.22 (the recent price), an insider wanted to purchase shares. While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. We always take careful note of the price insiders pay when purchasing shares. Generally speaking, it catches our eye when insiders have purchased shares at above current prices, as it suggests they believed the shares were worth buying, even at a higher price.

In the last twelve months Immix Biopharma insiders were buying shares, but not selling. They paid about US$3.03 on average. I'd consider this a positive as it suggests insiders see value at around the current price. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. By clicking on the graph below, you can see the precise details of each insider transaction!

Immix Biopharma is not the only stock insiders are buying. So take a peek at this free list of under-the-radar companies with insider buying.

Insider Ownership Of Immix Biopharma

Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. I reckon it's a good sign if insiders own a significant number of shares in the company. Insiders own 28% of Immix Biopharma shares, worth about US$17m. This level of insider ownership is good but just short of being particularly stand-out. It certainly does suggest a reasonable degree of alignment.

So What Do The Immix Biopharma Insider Transactions Indicate?

The recent insider purchases are heartening. And the longer term insider transactions also give us confidence. But we don't feel the same about the fact the company is making losses. Given that insiders also own a fair bit of Immix Biopharma we think they are probably pretty confident of a bright future. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Immix Biopharma. When we did our research, we found 6 warning signs for Immix Biopharma (3 can't be ignored!) that we believe deserve your full attention.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.